Wells Fargo & Company Cidara Therapeutics, Inc. Transaction History

Wells Fargo & Company

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.64 - $0.92 $6 - $9	10 Added 1.58%	643 $0
Q4 2023 Feb 09, 2024	BUY	$0.68 - $0.97 $23 - $32	34 Added 5.68%	633 $0
Q3 2023 Nov 13, 2023	BUY	$0.77 - $1.16 $21 - $32	28 Added 4.9%	599 $0
Q2 2023 Aug 15, 2023	BUY	$1.01 - $1.42 $136 - $191	135 Added 30.96%	571 $0
Q1 2023 May 12, 2023	BUY	$0.75 - $1.98 $5 - $13	7 Added 1.63%	436 $0
Q4 2022 Feb 13, 2023	BUY	$0.48 - $13.08 $9 - $261	20 Added 4.89%	429 $0
Q3 2022 Nov 14, 2022	BUY	$0.45 - $13.0 $5 - $156	12 Added 3.02%	409 $0
Q2 2022 Aug 12, 2022	BUY	$0.43 - $0.91 $18 - $40	44 Added 12.46%	397 $0
Q1 2022 May 16, 2022	BUY	$0.67 - $1.39 $0 - $1	1 Added 0.28%	353 $0
Q4 2021 Feb 14, 2022	BUY	$1.18 - $2.18 $132 - $244	112 Added 46.67%	352 $0
Q3 2021 Nov 15, 2021	SELL	$1.48 - $2.35 $44 - $70	-30 Reduced 11.11%	240 $1,000
Q2 2021 Aug 16, 2021	SELL	$1.87 - $2.7 $20,626 - $29,781	-11,030 Reduced 97.61%	270 $1,000
Q1 2021 May 13, 2021	SELL	$2.06 - $3.01 $131,796 - $192,576	-63,979 Reduced 84.99%	11,300 $30,000
Q4 2020 Feb 09, 2021	SELL	$1.99 - $3.25 $37,505 - $61,252	-18,847 Reduced 20.02%	75,279 $150,000
Q3 2020 Nov 05, 2020	BUY	$2.85 - $4.1 $93,212 - $134,094	32,706 Added 53.25%	94,126 $268,000
Q2 2020 Aug 13, 2020	BUY	$2.39 - $4.0 $142,800 - $238,996	59,749 Added 3575.64%	61,420 $227,000
Q1 2020 May 14, 2020	BUY	$1.74 - $4.26 $2,907 - $7,118	1,671 New	1,671 $4,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.43B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.